Pacira BioSciences (NASDAQ:PCRX) CFO Shawn Cross Sells 2,845 Shares

Pacira BioSciences, Inc. (NASDAQ:PCRX) CFO Shawn Cross sold 2,845 shares of the stock in a transaction on Tuesday, April 21st. The shares were sold at an average price of $25.01, for a total transaction of $71,153.45. Following the completion of the transaction, the chief financial officer owned 105,341 shares of the company’s stock, valued at approximately $2,634,578.41. This represents a 2.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shawn Cross also recently made the following trade(s):

• On Wednesday, April 22nd, Shawn Cross sold 1,500 shares of Pacira BioSciences stock. The shares were sold at an average price of $25.01, for a total transaction of $37,515.00.
• On Monday, April 20th, Shawn Cross sold 7,714 shares of Pacira BioSciences stock. The stock was sold at an average price of $25.14, for a total transaction of $193,929.96.

Pacira BioSciences Price Performance

Shares of Pacira BioSciences stock traded up $0.24 during mid-day trading on Wednesday, reaching $24.88. 360,574 shares of the stock were exchanged, compared to its average volume of 478,222. The company has a market cap of $1.01 billion, a price-to-earnings ratio of 165.87 and a beta of 0.19. The company has a current ratio of 4.54, a quick ratio of 3.28 and a debt-to-equity ratio of 0.54. The firm has a 50-day simple moving average of $22.96 and a 200 day simple moving average of $23.06. Pacira BioSciences, Inc. has a fifty-two week low of $18.80 and a fifty-two week high of $27.64.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.85 by ($0.28). The firm had revenue of $196.87 million for the quarter, compared to analyst estimates of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.The company’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the business earned $0.91 EPS. On average, sell-side analysts predict that Pacira BioSciences, Inc. will post 1.85 EPS for the current fiscal year.

Institutional Investors Weigh In On Pacira BioSciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Foster & Motley Inc. grew its holdings in Pacira BioSciences by 38.8% during the 1st quarter. Foster & Motley Inc. now owns 57,000 shares of the company’s stock worth $1,288,000 after acquiring an additional 15,943 shares during the last quarter. Louisiana State Employees Retirement System bought a new stake in Pacira BioSciences during the 1st quarter worth about $411,000. SG Americas Securities LLC grew its holdings in Pacira BioSciences by 28.0% during the 1st quarter. SG Americas Securities LLC now owns 24,303 shares of the company’s stock worth $549,000 after acquiring an additional 5,315 shares during the last quarter. Hsbc Holdings PLC grew its holdings in Pacira BioSciences by 7.7% during the 4th quarter. Hsbc Holdings PLC now owns 18,416 shares of the company’s stock worth $479,000 after acquiring an additional 1,316 shares during the last quarter. Finally, Vident Advisory LLC grew its holdings in Pacira BioSciences by 15.0% during the 4th quarter. Vident Advisory LLC now owns 23,571 shares of the company’s stock worth $610,000 after acquiring an additional 3,075 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Zacks Research upgraded shares of Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Needham & Company LLC reiterated a “buy” rating and set a $30.00 target price on shares of Pacira BioSciences in a research report on Friday, January 9th. Wall Street Zen cut shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, February 28th. Finally, Barclays dropped their target price on shares of Pacira BioSciences from $27.00 to $25.00 and set an “equal weight” rating for the company in a research report on Thursday, March 26th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Pacira BioSciences presently has an average rating of “Hold” and an average target price of $30.25.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.